GPP
RYTM icon

Great Point Partners’s Rhythm Pharmaceuticals RYTM Stock Holding History

Great Point Partners’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-772,000
Closed -$12.7M – 51
2023
Q2 		$12.7M Buy
772,000
+674,456
+691% +$12.2M 2.49% 18
2023
Q1 		$1.74M Buy
+97,544
New +$2.45M 0.34% 38

Other funds holding RYTM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Great Point Partners's RYTM Position: Q3 2023 in Review

Great Point Partners sold out of Rhythm Pharmaceuticals (RYTM) in Q3 2023, closing a stake of 772,000 shares — an estimated $12.7M sold.

Great Point Partners first reported a position in RYTM in Q1 2023 and held it in 2 quarters. The position peaked at $12.7M in Q2 2023. 143 funds tracked by Wall St. Rank hold RYTM as of Q3 2023.

  • Great Point Partners reported no remaining Rhythm Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Great Point Partners sold 772,000 Rhythm Pharmaceuticals shares in Q3 2023, an estimated $12.7M.
  • Great Point Partners first reported a position in Rhythm Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • Great Point Partners's Rhythm Pharmaceuticals position peaked at $12.7M in Q2 2023.
  • 143 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2023.

Based on Great Point Partners's 13F filing for Q3 2023, filed 14 Nov 2023.